New Zealand markets closed

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
9.730-0.570 (-5.53%)
As of 03:42PM HKT. Market open.
Full screen
Previous close10.300
Open10.480
Bid9.720 x 0
Ask9.730 x 0
Day's range9.710 - 10.560
52-week range9.470 - 33.700
Volume884,490
Avg. volume1,269,605
Market cap22.253B
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
EPS (TTM)-2.510
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est38.52
  • GlobeNewswire

    Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

    SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for toripalimab (product code: JS001) in combination with axitinib for the first-line treatment

  • GlobeNewswire

    Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

    SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased b

  • GlobeNewswire

    Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

    SHANGHAI, China, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Singapore Health Sciences Authority (“HSA") had accepted the New Drug Application (“NDA”) for toripalimab, both in combination with cisplatin and gemcitabine for the first-line treatment of adults with metas